Basic Information
| LncRNA/CircRNA Name | CCAT1 |
| Synonyms | CCAT1, CARLo-5, onco-lncRNA-40 |
| Region | GRCh38_8:127207382-127219268 |
| Ensemble | ENSG00000247844 |
| Refseq | NR_108049 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | multiple myeloma |
| ICD-0-3 | C42.1 |
| Methods | qPCR, Luciferase reporter assay, Western blot |
| Sample | cell lines (RPMI-8226, U266, MM.1S, KM3 and H929) |
| Expression Pattern | up-regulated |
| Function Description | the relative expression levels of CCAT1 were significantly upregulated in MM tissues and cell lines compared with healthy donors and normal plasma cells (nPCs). High expression of CCAT1 was correlated shorter overall survival of MM patients. CCAT1 knockdown significantly inhibited cell proliferation, induced cell cycle arrest at G0/G1 phase and promoted cell apoptosis in vitro, and suppressed tumor growth in vivo. MiR-181a-5p was a direct target of CCAT1, and repression of miR-181a-5p could rescue the inhibition of CCAT1 knockdown on MM progression. In addition,CCAT1 positively regulated HOXA1 expression through sponging miR-181a-5p in MM cells. lncRNA CCAT1 exerted an oncogenic role in MM by acting as a ceRNA of miR-181a-5p. These results suggest that CCAT1 may serve as a novel diagnostic marker and therapeutic target for MM. |
| Pubmed ID | 29228867 |
| Year | 2017 |
| Title | Long non-coding RNA CCAT1 promotes multiple myeloma progression by acting as a molecular sponge of miR-181a-5p to modulate HOXA1 expression. |
External Links
| Links for CCAT1 | GenBank HGNC NONCODE |
| Links for multiple myeloma | OMIM COSMIC |